Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dysmenorrhea

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    51 result(s) found for: Dysmenorrhea. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2015-004326-34 Sponsor Protocol Number: MK8342B-060 Start Date*: 2016-02-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3 Randomized, Double-blind, Placebo-Controlled Trial to Study the Efficacy and Safety of MK-8342B (ENG-E2 vaginal ring) in Women with Moderate to Severe Primary Dysmenorrhea.
    Medical condition: Moderate to severe primary dysmenorrhea
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004872 10062851 Primary dysmenorrhea LLT
    19.0 100000004872 10013934 Dysmenorrhea LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: SE (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-005031-17 Sponsor Protocol Number: BAY117031/19737 Start Date*: 2018-11-07
    Sponsor Name:Bayer HealthCare LLC
    Full Title: A Double-Blind, Randomized, Crossover Study to Assess Menstrual Cramp Pain Associated with Primary Dysmenorrhea
    Medical condition: Dysmenorrhea
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10062851 Primary dysmenorrhea LLT
    Population Age: Adolescents, Under 18 Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-004899-13 Sponsor Protocol Number: 310882 Start Date*: 2008-01-16
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: A multi-center, open-label, randomized, controlled, parallel-group study to assess efficacy and safety of an extended flexible regimen of the combined oral contraceptive SH T00186D (0.02 mg ethinyl...
    Medical condition: women suffering from primary dysmenorrhea
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004325-14 Sponsor Protocol Number: MK8342B-059 Start Date*: 2016-04-15
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Study the Efficacy and Safety of MK-8342B (ENG-E2 Vaginal Ring) in Women with Moderate to Severe Primary Dysmenorrhea (with Optional ...
    Medical condition: Treatment of primary dysmenorrhea
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004872 10062851 Primary dysmenorrhea LLT
    18.1 100000004872 10013934 Dysmenorrhea LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2012-002449-40 Sponsor Protocol Number: P057-00 Start Date*: 2012-10-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A multicenter, randomized, partially blinded, placebo-controlled clinical trial to evaluate the effect on primary dysmenorrheal of vaginal rings with an average daily release of 700 μg nomegestrol...
    Medical condition: This study will investigate the use of 4 doses of combined contraceptives (a progestin with an estrogen) in a vaginal ring dosage form for the treatment of dysmenorrhea (menstrual cramping pain). A...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) NO (Completed) NL (Completed) BE (Completed) SE (Completed) PL (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-006762-29 Sponsor Protocol Number: NL0804 Start Date*: 2009-01-16
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A double-blind, randomised, crossover, single dose, single centre, study examining the analgesic efficacy and tolerability of fixed-dose combinations of ibuprofen 200mg and acetaminophen 500mg, ibu...
    Medical condition: Primary Dysmenorrhoea
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036689 Primary dysmenorrhoea LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004138-41 Sponsor Protocol Number: LPS16145 Start Date*: 2020-07-02
    Sponsor Name:Sanofi-Aventis Groupe
    Full Title: A phase IV randomized, double-blind, 3-treatment, 3-period, 6-sequence crossover clinical trial to assess the efficacy and safety of hyoscine butylbromide co-administered with ibuprofen compared to...
    Medical condition: Dysmenorrhoea
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10013935 Dysmenorrhoea PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001588-19 Sponsor Protocol Number: MVT-601-3101 Start Date*: 2017-11-01
    Sponsor Name:Myovant Sciences GmbH
    Full Title: SPIRIT 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Ac...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) ES (Completed) HU (Completed) BE (Completed) PL (Completed) BG (Completed) PT (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2020-006147-25 Sponsor Protocol Number: UTEROXINE Start Date*: 2022-11-15
    Sponsor Name:Centre de Recherche en Santé de la Femme
    Full Title: Botulinum toxin type A injection in patients with chronic pelvic pain of uterine origin (severe dysmenorrhea and/or deep dyspareunia). Phase III, single-center, randomized study vs. control group
    Medical condition: PATIENTS WITH CHRONIC PELVIC PERINEAL PAIN OF UTERINE ORIGIN WITH VAS>4
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10048581 Pelvic pain female LLT
    21.1 10038604 - Reproductive system and breast disorders 10064189 Chronic pelvic pain syndrome LLT
    21.1 10037175 - Psychiatric disorders 10078087 Genito-pelvic pain/penetration disorder PT
    21.1 10038604 - Reproductive system and breast disorders 10011990 Deep dyspareunia LLT
    20.1 10038604 - Reproductive system and breast disorders 10013934 Dysmenorrhea LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001389-34 Sponsor Protocol Number: PSD508-DYS-001 Start Date*: 2007-10-30
    Sponsor Name:Plethora Solutions Limited
    Full Title: A multi-centre, double-blind, placebo-controlled, multiple-dose crossover proof of concept study to compare the efficacy of mefenamic acid administered vaginally and orally in healthy menstruating ...
    Medical condition: Primary dysmenorrhoea requiring analgesia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036689 Primary dysmenorrhoea LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012457-37 Sponsor Protocol Number: 913-002 Start Date*: 2009-08-13
    Sponsor Name:Vantia Ltd
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Cross-Over Proof of Concept Study to Investigate the Efficacy and Safety of Pre-Emptive Administration of Repeated, Oral Doses of VA1119...
    Medical condition: Dysmenorrhoea
    Disease: Version SOC Term Classification Code Term Level
    12.0 10013935 Dysmenorrhoea LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-003619-22 Sponsor Protocol Number: A2370327 Start Date*: 2004-11-26
    Sponsor Name:GlaxoSmithKline Consumer Healthcare
    Full Title: A placebo-controlled study to investigate the efficacy of a combination analgesic treatment compared to its individual components in primary dysmenorrhoea.
    Medical condition: primary dysmenorrhoea
    Disease: Version SOC Term Classification Code Term Level
    7.1 10013935
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-004066-10 Sponsor Protocol Number: MVT-601-3103 Start Date*: 2018-10-19
    Sponsor Name:Myovant Sciences GmbH
    Full Title: SPIRIT EXTENSION: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Co-Administered with Low-Dose Estradiol and Norethindrone Acetate in Wom...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) HU (Completed) BE (Completed) FI (Completed) SE (Completed) PL (Completed) CZ (Completed) BG (Completed) PT (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-001632-19 Sponsor Protocol Number: MVT-601-3102 Start Date*: 2017-12-01
    Sponsor Name:Myovant Sciences GmbH
    Full Title: SPIRIT 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Ac...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) CZ (Completed) PL (Completed) GB (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-002791-14 Sponsor Protocol Number: 1707-CL-0011 Start Date*: 2013-02-14
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Dose-Response Relationship of ASP1707 in Subjects with Endometriosis Associated Pelvic Pain for 12 ...
    Medical condition: endometriosis associated pelvic pain
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004872 10014788 Endometriosis related pain LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) BE (Completed) GB (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2022-000843-57 Sponsor Protocol Number: CRO22001 Start Date*: 2022-11-02
    Sponsor Name:RONTIS HELLAS S.A.
    Full Title: A double-blind, randomized, cross-over, multi-center efficacy and safety study of ibuprofen plus hyoscine butylbromide for pain management due to primary dysmenorrhea
    Medical condition: The efficacy and safety of ibuprofen plus hyoscine butylbromide for pain management due to primary dysmenorrhea will be investigated. Primary dysmenorrhea is the most common gynecological complaint...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002446-31 Sponsor Protocol Number: FMLD-HUNGRIA-28_FIII Start Date*: 2017-03-08
    Sponsor Name:LABORATORIOS FARMALIDER S.A.
    Full Title: Phase III clinical trial , multicenter , randomized , double-blind , crossover, active-controlled and placebo to evaluate the analgesic efficacy and safety of paracetamol / ibuprofen 500/200 mg com...
    Medical condition: MODERATE TO SEVERE PAIN FOLLOWING DYSMENORRHOEA
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003809-25 Sponsor Protocol Number: L-9134 Start Date*: 2004-12-20
    Sponsor Name:Sanofi-Synthelabo Co. Ltd.
    Full Title: Comparison of the efficacy and tolerability of drotaverine 80 mg or ibuprofen 400 mg administered alone with their combination for the treatment of primary and secondary dysmenorrhea
    Medical condition: A NO-SPA és az ibuprofen kombinációja elfogadott és Magyarországon gyakran használták a nőgyógyászati gyakorlatban sok évvel ezelőtt. A kombináció használatával kapcsolatos súlyos mellékhatásról ne...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020922-16 Sponsor Protocol Number: BAY 86-5028/15105 Start Date*: 2011-03-01
    Sponsor Name:Bayer Healthcare AG
    Full Title: International, prospective, double-blind, 3-arm comparative, randomized, placebo controlled phase IV study on the effect of counseling and either tranexamic acid or mefenamic acid or placebo, on th...
    Medical condition: Management of bleeding/spotting in women using the levonorgestrel-releasing intrauterine system (Mirena) for contraception.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10046883 Vaginal bleeding LLT
    Population Age: Adults Gender: Female
    Trial protocol: IE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-004752-21 Sponsor Protocol Number: ISI-06-01 Start Date*: 2006-11-08
    Sponsor Name:Karolinska Institute, Danderyds hospital
    Full Title: Pertubation with Lignocaine in Endometriosis Associated Symptoms Effect study (PLEASE)
    Medical condition: Women 20-40 years of age with endometriosis and pelvic pain will be included in this study.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10014788 Endometriosis related pain LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 10:41:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA